HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avon’s FY 2016 Marked By ‘Success Stories,’ But Not Enough Of Them

This article was originally published in The Rose Sheet

Executive Summary

Following steady improvements over the first three quarters of fiscal 2016, Avon ends the year on a sour note with a disappointing fourth quarter. However, the international direct seller exceeded its cost savings targets and is now embarking on the next phase of its transformation plan with greater focus on growth.

You may also be interested in...



Avon's Ongoing Struggles Prompt Renewed Investor Call For CEO Ouster

Management projects a strong second half after Avon's first-quarter sales advanced 2%, reported, but dipped in constant currency. Analysts received the guidance guardedly, and a group of investors led by Barington Capital are unconvinced the firm can turn things around under current leadership.

Avon Outlines Transformation, Cost-Savings Plan; Analysts Still Wary

Following Avon Products Inc.'s announcement last month that it will spin off its North American business, execs provide a strategy update for investors, including a $350m cost-savings plan.

Goop Exits NAD Review With Menopause Support Claim Affirmed For Madame Ovary Supplement

Gwyneth Paltrow’s Goop, Inc. demonstrated to the National Advertising Division’s satisfaction that Madame Ovary is “a daily regimen formulated to support thyroid health and smoothing the menopausal transition by providing nutritional support for women who may experience mild hot flashes, mood shifts, and stress-related fatigue.” Other ingredient-specific claims came up short.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel